Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A

Molecular Cancer Therapeutics

Volumn 8, Issue 6, 2009, Pages 1714-1723

  Gu, Yongchuan ^a   Patterson, Adam V ^a   Atwell, Graham J ^a   Chernikova, Sophia B ^b   Brown, J Martin ^b   Thompson, Larry H ^c   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b STANFORD UNIVERSITY   (United States)

^c LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; CHLORAMBUCIL; CHLORMETHINE DERIVATIVE; DRUG METABOLITE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MITOMYCIN C; PR 104A; PR 104H; PR 104M; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DNA CROSS LINKING; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; HOMOLOGOUS RECOMBINATION; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHLORAMBUCIL; CHO CELLS; CHROMATOGRAPHY, LIQUID; CRICETINAE; CRICETULUS; DNA REPAIR; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDONUCLEASES; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; MUTATION; NADPH-FERRIHEMOPROTEIN REDUCTASE; NITROGEN MUSTARD COMPOUNDS; RAD51 RECOMBINASE; TANDEM MASS SPECTROMETRY;

EID: 67649354921     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1209     Document Type: Article

References (50)

1. 2 histography. Antioxid Redox Signal 2007;9:1221-1235
2. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757. (Pubitemid 44832019)
3. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008;8:425-437 (Pubitemid 351744964)
4. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-447 (Pubitemid 38745529)
5. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-943 (Pubitemid 26065381)
6. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2α and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006;24:727-735 (Pubitemid 46622039)
7. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24.
8. Stadler P, Becker A, Feldmann HJ, et al. Influence of the hypoxic sub-volume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44:749-754 (Pubitemid 29284123)
9. Generali D, Berruti A, Brizzi MP, et al. Hypoxia-inducible factor-1 expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006;12:4562-4568 (Pubitemid 44297805)
10. Rauth AM, Melo T, Misra V. Bioreductive therapies: an overview of drugs and their mechanisms of action. Int J Radiat Oncol Biol Phys 1998;42:755-762 (Pubitemid 28559412)
11. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anticancer Drug Des 1998;13:519-528 (Pubitemid 28410146)
12. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999;59:5863-5870
13. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol 2007;19:427-442 (Pubitemid 46995614)
14. Chen Y, Hu L. Design of anticancer prodrugs for reductive activation. Med Res Rev 2009;29:29-64.
15. Patterson AV, Ferry DM, Edmunds SJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104. Clin Cancer Res 2007;13:3922-3932 (Pubitemid 47037600)
16. Jameson MB, Rischin D, Pegram M, et al. A phase I pharmacokinetic study of PR-104, a hypoxia-targeting agent, in patients with solid tumors. J Clin Oncol 2007;25:3516.
17. Helsby NA, Ferry DM, Patterson AV, Pullen SM, Wilson WR. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br J Cancer 2004;90:1084-1093
18. Siim BG, Denny WA, Wilson WR. Nitro reduction as an electronic switch for bioreductive drug activation. Oncol Res 1997;9:357-369 (Pubitemid 127825990)
19. Singleton RS, Guise CP, Ferry DM, et al. DNA crosslinks in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism and cytotoxicity. Cancer Res 2009;69:3884-3891
20. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000;20:7980-7990 (Pubitemid 30777715)
21. Bergstralh DT, Sekelsky J. Interstrand crosslink repair: can XPF-ERCC1 be let off the hook? Trends Genet 2008;24:70-76
22. Thompson LH, Hinz JM. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutat Res Fundam Mol Mech Mutagen 2009; doi: 10.1016/j.mrfmmm.2009.02.003.
23. Guise C, Wang A, Thiel A, et al. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 2007;74:810-820 (Pubitemid 47212075)
24. Denny WA, Atwell GJ, Yang S, et al., inventors; Auckland Uniservices Ltd., assignee. Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents. PCT/NZ 2004/529249. WO2005/042471A1. 2005.
25. Atwell GJ, Denny WA. Synthesis of 3H- and 2H4-labelled versions of the hypoxia-activated pre-prodrug 2-[(2-bromoethyl)-2,4-dinitro-6-[[[2- (phosphonooxy)ethyl]amino]carbonyl]anilino]ethyl methanesulfonate (PR-104). J Labelled Cmpd Radiopharm 2007;50:7-12. (Pubitemid 46456784)
26. Ferguson LR, Palmer BD, Denny WA. Microbial mutagenicity of chlorambucil, its half-mustard and mitomycin C: a modified screening strategy for genetic toxicology of bis-alkylating anti-tumour drugs. Anticancer Drug Des 1988;3:67-76. (Pubitemid 18163011)
27. Wilson WR, Anderson RF, Denny WA. Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia- selective cytotoxicity for 4-substituted derivatives of nitracrine. J Med Chem 1989;32:23-30.
28. Thompson LH, Fong S, Brookman K. Validation of conditions for efficient detection of HPRT and APRT mutations in suspension-cultured Chinese hamster ovary cells. Mutat Res 1980;74:21-36. (Pubitemid 10180124)
29. Busch DB, Cleaver JE, Glaser DA. Large-scale isolation of UV-sensitive clones of CHO cells. Somatic Cell Genet 1980;6:407-418 (Pubitemid 10113597)
30. Hoy CA, Thompson LH, Mooney CL, Salazar EP. Defective DNA crosslink removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Res 1985;45:1737-1743 (Pubitemid 15079132)
31. Thompson LH, Busch DB, Brookman K, Mooney CL, Glaser DA. Genetic diversity of UV-sensitive DNA repair mutants of Chinese hamster ovary cells. Proc Natl Acad Sci U S A 1981;78:3734-3737 (Pubitemid 11060452)
32. Brookman KW, Lamerdin JE, Thelen MP, et al. ERCC4 (XPF) encodes a human nucleotide excision repair protein with eukaryotic recombination homologs. Mol Cell Biol 1996;16:6553-6562 (Pubitemid 26361014)
33. Thompson LH, Rubin JS, Cleaver JE, Whitmore GF, Brookman K. A screening method for isolating DNA repair-deficient mutants of CHO cells. Somatic Cell Genet 1980;6:391-405. (Pubitemid 10113596)
34. Blunt T, Finnie NJ, Taccioli GE, et al. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell 1995;80:813-823
35. Hinz JM, Tebbs RS, Wilson PF, et al. Repression of mutagenesis by Rad51D-mediated homologous recombination. Nucleic Acids Res 2006;34:1358-1383
36. Ahn GO, Botting KJ, Patterson AV, et al. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochem Pharmacol 2006;71:1683-1694
37. Patterson AV, Saunders MP, Chinje EC, et al. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 1997;76:1338-1347
38. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85, Erratum in: Anal Biochem 1987;163(1):279. (Pubitemid 16258399)
39. Hay MP, Gamage SA, Kovacs MS, et al. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem 2003;46:169-182
40. Thompson LH, Brookman KW, Carrano AV, Dillehay LE. Role of DNA repair in mutagenesis of Chinese hamster ovary cells by 7-bromomethylbenz[a]anthracene. Proc Natl Acad Sci U S A 1982;79:534-538
41. Wilson WR, Thompson LH, Anderson RF, Denny WA. Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives. J Med Chem 1989;32:31-38
42. Han JF, Wang SL, He XY, Liu CY, Hong JY. Effect of genetic variation on human cytochrome p450 reductase-mediated paraquat cytotoxicity. Toxicol Sci 2006;91:42-48
43. Niedernhofer LJ, Odijk H, Budzowska M, et al. The structure-specific endonuclease Ercc1-Xpfis required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004;24:5776-5787 (Pubitemid 38787963)
44. Niedernhofer LJ. The Fanconi anemia signalosome anchor. Mol Cell 2007;25:478-490 (Pubitemid 46274451)
45. Patel K, Lewiston D, Gu Y, Hicks KO, Wilson WR. Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography- mass spectrometry. J Chromatog B 2007;856:302-311 (Pubitemid 47302931)
46. Helsby NA, Goldthorpe MA, Tang MHY, et al. Influence of mustard group structure on pathways of in vitro metabolism of anticancer N-(2-hydroxyethyl)-3, 5-dinitrobenzamide-2-mustard prodrugs. Drug Metab Dispos 2008;36:353-360 (Pubitemid 351185748)
47. 13C NMR study of 1-(13)C-chloroacetaldehyde, a metabolite of ifosfamide and cyclophosphamide, in the isolated perfused rabbit heart model. Initial observations on its cardiotoxicity and cardiac metabolism. Cell Mol Biol 1997;43:773-782
48. Denny WA, Wilson WR. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J Med Chem 1986;29:879-887 (Pubitemid 16068792)
49. Helsby NA, Wheeler SJ, Pruijn FB, et al. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5- aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Chem Res Toxicol 2003;16:469-478
50. Chan N, Koritzinsky M, Zhao H, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008;68:605-614